Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CODX | -0.02% | $21.73M | -43.28% | 0.00% |
CME | -0.03% | $88.08B | +19.81% | 4.26% |
PEG | 0.06% | $41.82B | +44.21% | 2.87% |
CBOE | 0.07% | $21.67B | +12.40% | 1.15% |
OKE | 0.08% | $59.79B | +38.93% | 4.19% |
AOUT | -0.17% | $226.69M | +98.66% | 0.00% |
WST | -0.20% | $23.93B | -19.57% | 0.18% |
NGL | 0.23% | $731.35M | -3.99% | 0.00% |
MDLZ | 0.23% | $77.33B | -22.65% | 3.08% |
REX | 0.24% | $740.46M | -2.54% | 0.00% |
JBLU | 0.25% | $2.25B | +12.07% | 0.00% |
VSTS | -0.27% | $1.81B | -31.63% | 1.01% |
UGP | 0.27% | $3.11B | -50.78% | 4.40% |
CNX | 0.27% | $4.35B | +44.41% | 0.00% |
ALL | -0.31% | $50.81B | +18.63% | 1.92% |
IMNN | -0.31% | $13.04M | +76.33% | 0.00% |
CRWD | 0.32% | $103.58B | +30.17% | 0.00% |
COR | -0.38% | $47.71B | +6.86% | 0.84% |
SRRK | -0.39% | $3.81B | +159.20% | 0.00% |
WEC | 0.40% | $31.89B | +30.22% | 3.31% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
MEAR | 0.01% | $771.64M | 0.25% |
CMDY | -0.02% | $288.94M | 0.28% |
TAXF | -0.11% | $524.56M | 0.29% |
OILK | -0.15% | $73.58M | 0.69% |
BNO | -0.15% | $96.30M | 1% |
STPZ | -0.19% | $432.93M | 0.2% |
DBC | 0.30% | $1.35B | 0.87% |
BWZ | 0.30% | $133.76M | 0.35% |
IYK | -0.41% | $1.21B | 0.4% |
USO | -0.41% | $1.07B | 0.6% |
PDBC | 0.44% | $4.37B | 0.59% |
FTSD | -0.49% | $201.10M | 0.25% |
UTWO | 0.53% | $386.83M | 0.15% |
BILS | 0.57% | $3.37B | 0.1356% |
GSG | -0.70% | $1.05B | 0.75% |
TBIL | 0.74% | $4.83B | 0.15% |
BOXX | -0.89% | $5.02B | 0.1949% |
SPTS | -0.90% | $5.80B | 0.03% |
FTGC | -0.91% | $2.44B | 1.02% |
NYF | -0.96% | $837.29M | 0.25% |
Finnhub
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
Yahoo
Sentynl took over the therapy’s development and commercialisation from Fortress Biotech's subsidiary Cyprium Therapeutics.
Finnhub
Solana Beach, Ahmedabad, India - Sentynl Therapeutics, Inc. , a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. , and Fortress Biotech, Inc. announced that the U.S....
Yahoo
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced the acceptance for
Yahoo
Sentynl Therapeutics, Inc. ("Sentynl"), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. ("Zydus Group"), and Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and Priority review Sentynl's New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease. Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the c
Yahoo
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinomaWALTHAM, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has approved UNLOXCYT™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (“cSCC”) or locally advanced cSCC who are not candidates for curative surgery or curative r
Current Value
$1.851 Year Return
Current Value
$1.851 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CL | -13.40% | $70.00B | +1.69% | 2.33% |
PULM | -12.04% | $27.68M | +351.19% | 0.00% |
VHC | -9.72% | $33.67M | +28.58% | 0.00% |
KO | -9.37% | $272.94B | +5.90% | 3.06% |
TMUS | -9.29% | $282.20B | +53.59% | 1.14% |
EW | -9.15% | $41.87B | -17.26% | 0.00% |
CHD | -8.82% | $25.82B | +5.46% | 1.08% |
HLN | -8.63% | $43.05B | +14.99% | 1.65% |
CLX | -8.59% | $18.18B | -4.29% | 3.29% |
DOUG | -7.38% | $175.66M | +9.44% | 0.00% |
BRFS | -7.33% | $6.06B | +32.53% | 0.00% |
NNE | -6.52% | $1.11B | +739.00% | 0.00% |
TIMB | -6.51% | $6.48B | -27.27% | 3.90% |
MMM | -6.25% | $82.17B | +95.48% | 2.36% |
T | -6.13% | $175.44B | +45.36% | 4.55% |
HIG | -5.86% | $32.90B | +26.47% | 1.70% |
PG | -5.38% | $396.00B | +6.45% | 2.38% |
TEM | -5.33% | $10.23B | 0.00% | 0.00% |
TXO | -5.32% | $775.72M | +5.63% | 12.55% |
ADBE | -5.04% | $189.53B | -29.30% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MGTX | 38.46% | $543.17M | +10.49% | 0.00% |
NTLA | 38.41% | $1.03B | -63.12% | 0.00% |
PLRX | 37.05% | $727.20M | -26.64% | 0.00% |
CYRX | 36.08% | $346.51M | -55.46% | 0.00% |
GPRO | 35.32% | $167.14M | -58.14% | 0.00% |
VSH | 34.60% | $2.39B | -19.54% | 2.27% |
DMRC | 33.87% | $753.39M | -10.80% | 0.00% |
GBIO | 33.55% | $53.82M | -58.04% | 0.00% |
ARWR | 33.43% | $2.56B | -33.61% | 0.00% |
MLKN | 33.30% | $1.50B | -19.56% | 3.42% |
VYGR | 32.84% | $305.90M | -25.13% | 0.00% |
RGNX | 32.81% | $417.67M | -48.25% | 0.00% |
CLFD | 32.72% | $521.77M | +29.19% | 0.00% |
BEAM | 32.62% | $2.29B | -1.64% | 0.00% |
PLL | 31.99% | $179.79M | -43.72% | 0.00% |
DIOD | 31.97% | $2.64B | -17.05% | 0.00% |
IPGP | 31.85% | $3.06B | -29.89% | 0.00% |
SEER | 31.76% | $137.39M | +30.90% | 0.00% |
PLAB | 31.30% | $1.45B | -27.61% | 0.00% |
FATE | 31.29% | $159.45M | -77.09% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 40.70% | $71.39M | 0.5% |
IWC | 39.97% | $977.29M | 0.6% |
CPRJ | 39.52% | $51.17M | 0.69% |
ARKG | 38.84% | $1.25B | 0.75% |
PBW | 38.63% | $266.75M | 0.65% |
XBI | 38.01% | $6.19B | 0.35% |
PBE | 37.34% | $259.08M | 0.58% |
VTWO | 35.54% | $11.91B | 0.1% |
IWM | 35.38% | $74.54B | 0.19% |
IWO | 35.12% | $12.87B | 0.24% |
IBB | 35.00% | $6.68B | 0.45% |
KOMP | 34.67% | $2.21B | 0.2% |
KAPR | 34.66% | $164.93M | 0.79% |
ISCG | 34.66% | $681.17M | 0.06% |
PRFZ | 34.64% | $2.67B | 0.39% |
SCHA | 34.52% | $18.95B | 0.04% |
PTH | 34.21% | $130.98M | 0.6% |
IWN | 34.10% | $12.43B | 0.24% |
NUSC | 34.01% | $1.28B | 0.31% |
ACES | 33.92% | $98.83M | 0.55% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -27.67% | $272.15M | 1.43% |
TAIL | -15.50% | $65.47M | 0.59% |
VIXY | -15.14% | $195.31M | 0.85% |
AGZD | -8.36% | $137.11M | 0.23% |
GBIL | -8.33% | $5.79B | 0.12% |
CTA | -7.91% | $641.27M | 0.76% |
TFLO | -7.04% | $6.49B | 0.15% |
SPYT | -6.99% | $97.98M | 0.94% |
XBIL | -6.58% | $647.00M | 0.15% |
USFR | -6.57% | $17.57B | 0.15% |
UNG | -5.93% | $717.51M | 1.06% |
XHLF | -5.81% | $1.07B | 0.03% |
DBA | -5.43% | $876.36M | 0.93% |
WEAT | -5.24% | $124.48M | 0.28% |
CLOI | -5.01% | $873.72M | 0.4% |
DUSB | -4.99% | $1.02B | 0.15% |
MINT | -4.90% | $12.28B | 0.35% |
JUCY | -4.83% | $309.21M | 0.6% |
CORN | -4.73% | $66.02M | 0.2% |
BIL | -4.73% | $37.18B | 0.1356% |